Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Teriparatide better than risedronate for preventing fractures despite psychotropic, PPI exposure

20 Nov 2019

Exposure to psychotropic drugs and proton pump inhibitors (PPIs) contributes to an increase risk of clinical and nonvertebral fractures in postmenopausal women with severe osteoporosis, according to a study. Furthermore, teriparatide confers superior benefits for reducing the risk of fractures compared with risedronate, irrespective of such an exposure.

Researchers conducted a posthoc analysis of the fracture-endpoint study VERO, which evaluated the effect of subcutaneous daily teriparatide 20 μg vs oral weekly risedronate 35 mg in women with established osteoporosis. They assessed the risk of fractures in relation to exposure to psychotropic drugs (hypnotics, benzodiazepines and antidepressants) and proton pump inhibitors (PPIs), including potential interactions with the assigned clinical trial drugs.

Of the women, 406 (29.9 percent) were exposed to PPIs, 347 (25.5 percent) to benzodiazepines/hypnotics, and 176 (12.9 percent) to selective serotonin- and norepinephrine-reuptake inhibitors (SSRIs/SNRIs) during the study. The risk-reduction advantage observed with teriparatide vs risedronate for all fracture endpoints did not significantly differ within the categories of psychotropic drugs and PPIs.

Multivariable analysis showed that PPI use vs nonuse was associated with a heightened risk of pooled new and worsened vertebral fractures (risk ratio, 1.57; p=0.032), regardless of the study treatment. On the other hand, benzodiazepine/hypnotic drug use was associated with increased risks of clinical fractures (hazard ratio [HR], 1.71; p=0.026) and nonvertebral fragility fractures (HR, 1.89; p=0.017), regardless of the study treatment.

Likewise, SSRI/SNRI use contributed to an increased risk of clinical fractures (HR, 1.93; p=0.018) and nonvertebral fragility fractures (HR, 2.16; p=0.011), regardless of the study treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).